Provider Briefing: Cartia XT (Diltiazem ER) Supply in 2026

If your patients are calling about unfilled Cartia XT prescriptions, this post is your quick-reference guide to the current supply landscape, prescribing considerations, and tools you can use to help patients maintain access to their Diltiazem therapy.

This briefing covers brand-name Cartia XT and generic Diltiazem Hydrochloride extended-release capsules (once-daily formulations), manufactured primarily by Teva Pharmaceuticals (brand) and multiple generic manufacturers.

Supply Timeline and Current Status

Injectable Diltiazem (Hospital Setting)

Diltiazem Hydrochloride injection has been on the ASHP/FDA drug shortage list since June 2015. Akorn discontinued its Diltiazem injection in mid-2022, further constraining supply. As of early 2026, Hikma has Diltiazem injection 5 mg/mL in 5 mL and 25 mL vials on allocation, with 10 mL vials on back order. This is primarily a hospital-use concern and does not directly affect outpatient prescribing.

Oral Extended-Release Capsules (Outpatient)

Oral Diltiazem ER capsules — including Cartia XT and generic equivalents — are not currently on the FDA's official shortage list. However, real-world availability remains inconsistent:

• Patients report intermittent stock-outs at retail chain pharmacies (CVS, Walgreens, Rite Aid)
• Certain strengths (particularly 180 mg and 300 mg) may be harder to source in some regions
• Independent pharmacies and mail-order services generally report better availability
• Supply has improved compared to 2023-2024, but localized disruptions continue

Contributing Factors

• Manufacturing consolidation: Fewer companies producing generic Diltiazem ER means less redundancy in the supply chain
• Wholesaler allocation: When supply tightens, wholesalers may prioritize certain pharmacy accounts, creating uneven distribution
• Lean pharmacy inventory: Just-in-time ordering at chain pharmacies makes them vulnerable to short-term demand spikes

Prescribing Implications

Non-Interchangeability of Diltiazem ER Formulations

This is the most important clinical consideration: not all Diltiazem extended-release products are interchangeable. Different brands use distinct extended-release technologies that affect pharmacokinetics:

• Cartia XT / Cardizem CD / generic Dilt-CD: Once-daily capsules using similar release mechanisms — these are generally considered AB-rated interchangeable
• Tiazac / Taztia XT / Tiadylt ER: Once-daily capsules, but not AB-rated to Cartia XT — require a new prescription to switch
• Cardizem LA / Matzim LA: Once-daily tablets (not capsules) with a different release profile — not interchangeable with capsule formulations
• Dilacor XR / Dilt-XR: Once-daily capsules with their own release profile — not interchangeable with Cartia XT

Clinical recommendation: When switching between Diltiazem ER formulations, write a new prescription specifying the exact product. Monitor blood pressure and heart rate at 1-2 weeks post-switch to confirm therapeutic equivalence for that patient.

Therapeutic Alternatives

When Diltiazem ER is completely unavailable, consider these alternatives based on the clinical indication:

For hypertension:

• Verapamil ER — Most pharmacologically similar; also a non-dihydropyridine CCB with rate-lowering properties
• Amlodipine — Effective, widely available, but no heart rate effect; consider if rate control is not needed
• Nifedipine ER — Another dihydropyridine CCB option; no rate-lowering effect

For angina prophylaxis:

• Verapamil ER — Similar efficacy for angina prevention
• Amlodipine — FDA-approved for chronic stable angina
• Beta-blockers (Metoprolol Succinate ER) — Different mechanism but effective for angina; may be preferred if patient also has heart failure

For off-label rate control (atrial fibrillation):

• Verapamil ER — Comparable rate control efficacy
• Beta-blockers (Metoprolol, Atenolol) — First-line alternatives for rate control

For a patient-facing version of this information, see alternatives to Cartia XT.

Availability and Access Picture

The following channels tend to have better Diltiazem ER availability than chain retail pharmacies:

• Independent pharmacies: Often use different wholesalers and can special-order more flexibly
• Mail-order pharmacies: Maintain larger inventories; Rx Outreach (nonprofit), Amazon Pharmacy, and insurance-based mail-order programs are reliable options
• 90-day prescriptions: Reduce the frequency of refills and the chance of encountering a stock-out
• Real-time stock checking: Medfinder for Providers allows you to check pharmacy inventory in real time and direct patients to pharmacies that have their medication in stock

Cost and Access Considerations

Generic Diltiazem ER remains affordable for most patients:

• Cash price: $24-$37 for 90 capsules (varies by strength)
• With discount cards: $10-$25 for a 30-day supply via GoodRx or SingleCare
• Insurance: Typically Tier 1 or Tier 2 on most formularies; copays usually $0-$20
• Patient assistance: Patient Access Network (PAN) Foundation and HealthWell Foundation offer copay support for eligible patients

Cost is generally not the barrier to access for this medication — availability is. Patients who can find it can usually afford it.

Tools and Resources for Your Practice

Medfinder for Providers

Medfinder is a free tool that helps providers and their staff check real-time medication availability at pharmacies near the patient's location. You can:

• Verify stock before sending a prescription
• Direct patients to specific pharmacies that have their medication
• Reduce callback volume from patients with unfilled prescriptions

Patient Education Materials

Share these resources with patients experiencing access issues:

• How to find Cartia XT in stock near you
• Cartia XT shortage update for patients
• How to save money on Cartia XT

Prescribing Tips to Improve Fill Rates

1. Write for generic Diltiazem ER capsules when possible — broadens the products the pharmacy can dispense
2. Specify "may substitute" generically but be explicit about the formulation type (once-daily capsule)
3. Use 90-day quantities to reduce refill frequency
4. Include "or equivalent Diltiazem ER capsule" in notes if your state and clinical judgment allow
5. Have staff check Medfinder before e-prescribing to route to a pharmacy with confirmed stock

Looking Ahead

The oral Diltiazem ER supply situation is expected to remain stable-to-improving in 2026. Multiple generic manufacturers are in production, and the medication is not subject to the kind of regulatory or raw-material constraints that drive more severe shortages. However, the systemic factors that cause intermittent localized disruptions — lean inventory, wholesaler allocation, demand variability — are unlikely to fully resolve.

Providers can minimize patient impact by proactively prescribing in ways that maximize fill flexibility, educating patients about generic alternatives, and using real-time tools like Medfinder to verify availability before prescribing.

Final Thoughts

Cartia XT (Diltiazem ER) is not in a formal shortage, but your patients' frustration is real. The disconnect between national supply and local pharmacy stock creates genuine access barriers. The best thing you can do is stay informed, prescribe flexibly, and point patients toward the tools that help them find their medication.

For a step-by-step guide on helping patients locate Cartia XT, see our companion post: How to help your patients find Cartia XT in stock.